Is Melexis NV (EBR:MELE) Potentially Undervalued?HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 19 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Is Melexis NV (EBR:MELE) Potentially Undervalued?Simply Wall StSimply Wall St.January 10, 2020ReblogShareTweetShareView photosMelexis NV (EBR:MELE), which is in the semiconductor business, and is based in Belgium, saw a decent share price growth in the teens level on the ENXTBR over the last few months. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. However, could the stock still be trading at a relatively cheap price? Today I will analyse the most recent data on Melexis’s outlook and valuation to see if the opportunity still exists. See our latest analysis for Melexis Is Melexis still cheap?Melexis appears to be overvalued by 27% at the moment, based on my discounted cash flow valuation. The stock is currently priced at €68.95 on the market compared to my intrinsic value of €54.15. This means that the buying opportunity has probably disappeared for now. If you like the stock, you may want to keep an eye out for a potential price decline in the future. Since Melexis’s share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.Can we expect growth from Melexis?ENXTBR:MELE Past and Future Earnings, January 10th 2020MoreInvestors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Melexis’s earnings over the next few years are expected to increase by 70%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.What this means for you:Are you a shareholder? MELE’s optimistic future growth appears to have been factored into the current share price, with shares trading above its fair value. At this current price, shareholders may be asking a different question – should I sell? If you believe MELE should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.Are you a potential investor? If you’ve been keeping tabs on MELE for some time, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there’s no upside from mispricing. However, the optimistic prospect is encouraging for MELE, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Melexis. You can find everything you need to know about Melexis in the latest infographic research report. If you are no longer interested in Melexis, you can use our free platform to see my list of over 50 other stocks with a high growth potential.If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextSome ISS (CPH:ISS) Shareholders Have Copped A Big 57% Share Price DropSimply Wall St.Here's What Absolent Group AB (publ)'s (STO:ABSO) P/E Is Telling UsSimply Wall St.Timeless Software (HKG:8028) Shareholders Have Enjoyed A 51% Share Price GainSimply Wall St.Is There Now An Opportunity In NetDragon Websoft Holdings Limited (HKG:777)?Simply Wall St.Imagine Owning CommsChoice Group (ASX:CCG) And Wondering If The 36% Share Price Slide Is JustifiedSimply Wall St.Biocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoCrocs CEO explains its major turnaroundYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoPublic Joint-stock Company TNS energo Mari El (MCX:MISB) Is Yielding 7.0% - But Is It A Buy?Simply Wall St.What the GM strike means for the U.S. economyYahoo FinanceWhy negative interest rates are 'seriously dangerous': strategistYahoo FinanceAurora Cannabis tumbles after double downgradeYahoo Finance VideoCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video